**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531. doi: 10.1002/psp4.12134. Epub 2016 Oct 19. 	

**PK-Sim Ontogeny Database Version 7.3** (https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf)	

**Schlender 2016** Schlender JF, Meyer M, Thelen K, Krauss M, Willmann S, Eissing T, Jaehde U. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals. Clin Pharmacokinet. 2016 Dec;55(12):1573-1589. 	

**Dummy YEAR** Dummy D, Doe J, Doe A. Pharmackoniteic study of COMPOUND. JOURNAL. YEAR Mon;ISSUE:PAGES. doi: DOI.	



***Erythromycin-Alfentanil-DDI***

**Bartkowski 1989** Bartkowski, R. R., Goldberg, M. E., Larijani, G. E., & Boerner, T. (1989). Inhibition of alfentanil metabolism by erythromycin. *Clinical Pharmacology & Therapeutics*, *46*(1), 99-102.

**Bartkowski 1993** Bartkowski, R. R., Goldberg, M. E., Huffnagle, S., & Epstein, R. H. (1993). Sufentanil disposition. Is it affected by erythromycin administration?. *Anesthesiology*, *78*(2), 260-265.



***Erythromycin-Alprazolam-DDI***

**Yasui 1996** Yasui, N., Otani, K., Kaneko, S., Ohkubo, T., Osanai, T., Sugawara, K., ... & Ishizaki, T. (1996). A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. *Clinical Pharmacology & Therapeutics*, *59*(5), 514-519.



***Erythromycin-Triazolam-DDI***

**Greenblatt 1998** Greenblatt, D. J., von Moltke, L. L., Harmatz, J. S., Counihan, M., Graf, J. A., Durol, A. L. B., ... & Shader, R. I. (1998). Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. *Clinical Pharmacology & Therapeutics*, *64*(3), 278-285.

**Phillips 1986** Phillips, J. P., Antal, E. J., & Smith, R. B. (1986). A pharmacokinetic drug interaction between erythromycin and triazolam. *Journal of clinical psychopharmacology*, *6*(5), 297-299.



***Itraconazole-Midazolam-DDI***

**Ahonen 1995** Ahonen J, Olkkola KT, Neuvonen PJ. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol. 1995 Sep;40(3):270-2.

**Backman 1998** Backman JT, Kivist√∂ KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol. 1998 Mar;54(1):53-8.

**Olkkola 1994** Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994 May;55(5):481-5.

**Olkkola 1996** Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg. 1996 Mar;82(3):511-6.

**Prueksaritanont 2017** Prueksaritanont T, Tatosian DA, Chu X, Railkar R, Evers R, Chavez-Eng C, Lutz R, Zeng W, Yabut J, Chan GH, Cai X, Latham AH, Hehman J, Stypinski D, Brejda J, Zhou C, Thornton B, Bateman KP, Fraser I,, Stoch SA. Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. Clin Pharmacol Ther. 2017 Apr;101(4):519-530.

**Templeton 2010** Templeton I, Peng CC, Thummel KE, Davis C, Kunze KL, Isoherranen N. Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clin Pharmacol Ther. 2010 Oct;88(4):499-505.



***Rifampicin-Midazolam-DDI***